Vaderis Therapeutics

$152.0M Series B

Announced: Aug 11, 2026
Sector: Biotechnology
Investors: 8

Summary

Vaderis Therapeutics closed a USD 152 million Series B financing to support the initiation of its global Phase 3 HEROIC study and further development of engasertib for hereditary hemorrhagic telangiectasia. EQT Life Sciences said it is investing USD 17.5 million as part of the round. Vaderis Therapeutics is a science-driven biopharmaceutical company.

Investors

EQT Life Sciences, Life Sciences at Goldman Sachs Alternatives, TCGX, Omega Funds, Perceptive Advisors, Kalehua Capital, Medicxi, Droia